Edwards Lifesciences stock price target maintained at $85 by Canaccord
Canaccord maintained a Hold rating and $85 price target for Edwards Lifesciences (EW) after a Medicare coverage decision on TAVR procedures. The stock trades at $86.77, above the target but below consensus. CMS finalized changes Edwards requested, expanding coverage for asymptomatic severe aortic stenosis. Edwards confirmed its 2026 financial guidance, expecting long-term benefits. Analysts have mixed price targets, ranging from $84 to $110. The company reported strong Q2 results, with sales of
How this was made
The 30-second read
Why it matters
The CMS decision formalizes Medicare coverage for asymptomatic severe aortic stenosis, removing volume caps and adding workflow flexibility, which could expand the addressable market.
Market read
Regulatory win and earnings beat together create a fresh catalyst for EW, likely influencing short‑term price action.
What to watch
Potential reimbursement rate negotiations and competitive pressure from rival TAVR manufacturers.
Background
Edwards Lifesciences (EW) is a leading provider of transcatheter aortic valve replacement (TAVR) devices.
Ticker impact
Canaccord reiterates Hold and $85 target after CMS finalizes Medicare coverage for Edwards' TAVR procedures and after the company posted strong Q2 results.
Potential upside of 5‑7% over the next few weeks if market digests the coverage decision.
New Medicare policy removes volume thresholds, enabling new TAVR centers and supporting revenue growth; earnings beat reinforces growth outlook.
Market effects
TAVR and broader cardiovascular device sector may see increased investor interest.
U.S. healthcare stocks could benefit from the CMS policy change.
International medtech firms with TAVR pipelines may experience secondary valuation pressure.
Counterpoint
If new center approvals lag, the coverage decision may not translate into near‑term revenue, limiting upside.
Key entities
- analystCanaccord
Reiterated Hold rating and $85 price target.
- regulatorCMS
Issued final TAVR National Coverage Determination.
